Novartis AG Share Holder Equity 2010-2024 | NVS

Novartis AG share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Novartis AG share holder equity for the quarter ending March 31, 2024 was $39.756B, a 23.75% decline year-over-year.
  • Novartis AG share holder equity for 2023 was $46.75B, a 21.33% decline from 2022.
  • Novartis AG share holder equity for 2022 was $59.423B, a 12.38% decline from 2021.
  • Novartis AG share holder equity for 2021 was $67.822B, a 19.69% increase from 2020.
Novartis AG Annual Share Holder Equity
(Millions of US $)
2023 $46,750
2022 $59,423
2021 $67,822
2020 $56,666
2019 $55,551
2018 $78,692
2017 $74,227
2016 $74,891
2015 $77,122
2014 $70,844
2013 $74,472
2012 $69,263
2011 $65,940
2010 $69,769
2009 $57,462
Novartis AG Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $39,756
2023-12-31 $46,750
2023-09-30 $38,245
2023-06-30 $51,931
2023-03-31 $52,142
2022-12-31 $59,423
2022-09-30 $60,898
2022-06-30 $63,006
2022-03-31 $61,704
2021-12-31 $67,822
2021-09-30 $56,937
2021-06-30 $54,128
2021-03-31 $50,589
2020-12-31 $56,666
2020-09-30 $54,554
2020-06-30 $53,885
2020-03-31 $50,977
2019-12-31 $55,551
2019-09-30 $52,598
2019-06-30 $51,504
2019-03-31 $47,307
2018-12-31 $78,692
2018-09-30 $78,019
2018-06-30 $76,901
2018-03-31 $71,211
2017-12-31 $74,227
2017-09-30 $72,370
2017-06-30 $69,978
2017-03-31 $67,646
2016-12-31
2016-09-30 $75,066
2016-06-30 $72,532
2016-03-31 $71,889
2015-12-31 $77,122
2015-09-30 $76,785
2015-06-30 $78,832
2015-03-31 $76,444
2014-12-31 $70,844
2014-09-30 $71,424
2014-06-30 $70,517
2014-03-31 $70,336
2013-12-31 $74,472
2013-09-30 $72,179
2013-06-30 $69,628
2013-03-31 $67,148
2012-12-31 $69,263
2012-09-30 $67,205
2012-06-30 $64,241
2012-03-31 $63,201
2011-12-31 $65,940
2011-09-30 $66,141
2011-06-30 $67,093
2011-03-31 $65,340
2010-12-31 $69,769
2010-09-30 $66,218
2010-06-30 $55,816
2010-03-31 $55,216
2009-12-31 $57,462
2009-09-30 $53,313
2009-06-30 $50,488
2009-03-31 $46,228
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $215.744B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
AstraZeneca (AZN) United Kingdom $248.255B 21.58
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97